Skip to main content
Top
Published in: Cancer Causes & Control 4/2006

01-05-2006 | Special Section on Cancer and Rhythm

The Use of Chronobiotics in the Resynchronization of the Sleep–wake Cycle

Authors: Daniel P. Cardinali, Analía M. Furio, María P. Reyes, Luis I. Brusco

Published in: Cancer Causes & Control | Issue 4/2006

Login to get access

Abstract

Treatment of circadian rhythm disorders, whether precipitated by intrinsic factors (e.g., sleep disorders, blindness, mental disorders, aging) or by extrinsic factors (e.g., shift work, jet-lag) has led to the development of a new type of agents called ‘chronobiotics’, among which melatonin is the prototype. The term ‘chronobiotic’ defines as a substance capable of shifting the phase of the circadian time system thus re-entraining circadian rhythms. Melatonin administration synchronizes the sleep–wake cycle in blind people and in individuals suffering from delayed sleep phase syndrome or jet lag, as well in shift-workers. The effect of melatonin on sleep is probably the consequence of increasing sleep propensity (by inducing a fall in body temperature) and of a synchronizing effect on the circadian clock (chronobiotic effect). We successfully employed the timely use of three factors (melatonin treatment, exposure to light, physical exercise) to hasten the resynchronization after transmeridian flights comprising 12–13 time zones, from an average of 8–10 days to about 2 days. Daily melatonin production decreases with age, and in several pathologies, attaining its lowest values in Alzheimer’s dementia patients. About 45% of dementia patients have severe disruptions in their sleep–wakefulness cycle. Both in aged subjects having very minimal sleep disorders as well as in demented patients with a very severe disorganization of the sleep–wake cycle, melatonin treatment reduced the variability of sleep onset and restored sleep.
Literature
1.
go back to reference Buijs RM, Van Eden CG, Goncharuk VD, Kalsbeek A (2003) The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J Endocrinol 177:17–26CrossRefPubMed Buijs RM, Van Eden CG, Goncharuk VD, Kalsbeek A (2003) The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system. J Endocrinol 177:17–26CrossRefPubMed
2.
go back to reference Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4:649–661CrossRefPubMed Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4:649–661CrossRefPubMed
3.
go back to reference Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U (2004) The mammalian circadian timing system: from gene expression to physiology. Chromosoma 113:103–112CrossRefPubMed Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U (2004) The mammalian circadian timing system: from gene expression to physiology. Chromosoma 113:103–112CrossRefPubMed
4.
go back to reference Smolensky MH, Haus E (2001) Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens 14:280S–290SCrossRefPubMed Smolensky MH, Haus E (2001) Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens 14:280S–290SCrossRefPubMed
5.
go back to reference Cermakian N, Boivin DB (2003) A molecular perspective of human circadian rhythm disorders. Brain Res Brain Res Rev 42:204–220CrossRefPubMed Cermakian N, Boivin DB (2003) A molecular perspective of human circadian rhythm disorders. Brain Res Brain Res Rev 42:204–220CrossRefPubMed
6.
go back to reference Folkard S, Tucker P (2003) Shift work, safety and productivity. Occup Med (Lond) 53:95–101CrossRef Folkard S, Tucker P (2003) Shift work, safety and productivity. Occup Med (Lond) 53:95–101CrossRef
7.
go back to reference Knutsson A, Boggild H (2000) Shift work and cardiovascular disease: review of disease mechanisms. Rev Environ Health 15:359–372PubMed Knutsson A, Boggild H (2000) Shift work and cardiovascular disease: review of disease mechanisms. Rev Environ Health 15:359–372PubMed
8.
go back to reference Hobson JA, Pace-Schott EF (2002) The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat Rev Neurosci 3:679–693CrossRefPubMed Hobson JA, Pace-Schott EF (2002) The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat Rev Neurosci 3:679–693CrossRefPubMed
9.
go back to reference Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3:591–605PubMed Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3:591–605PubMed
10.
go back to reference Dorrian J, Lamond N, Holmes AL, etal. (2003) The ability to self-monitor performance during a week of simulated night shifts. Sleep 26:871–877PubMed Dorrian J, Lamond N, Holmes AL, etal. (2003) The ability to self-monitor performance during a week of simulated night shifts. Sleep 26:871–877PubMed
11.
go back to reference Lamond N, Dorrian J, Roach GD, etal. (2003) The impact of a week of simulated night work on sleep, circadian phase, and performance. Occup Environ Med 60:e13CrossRefPubMed Lamond N, Dorrian J, Roach GD, etal. (2003) The impact of a week of simulated night work on sleep, circadian phase, and performance. Occup Environ Med 60:e13CrossRefPubMed
12.
go back to reference Dawson D, Armstrong SM (1996) Chronobiotics – drugs that shift rhythms. Pharmacol Ther 69:15–36CrossRefPubMed Dawson D, Armstrong SM (1996) Chronobiotics – drugs that shift rhythms. Pharmacol Ther 69:15–36CrossRefPubMed
13.
go back to reference Reiter RJ, Tan DX, Burkhardt S, Manchester LC (2001) Melatonin in plants. Nutr Rev 59:286–290PubMed Reiter RJ, Tan DX, Burkhardt S, Manchester LC (2001) Melatonin in plants. Nutr Rev 59:286–290PubMed
14.
15.
16.
go back to reference Lewy AJ, Bauer VK, Ahmed S, etal. (1998) The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 15:71–83PubMed Lewy AJ, Bauer VK, Ahmed S, etal. (1998) The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 15:71–83PubMed
17.
go back to reference Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8:D1093–D1108PubMed Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI (2003) Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 8:D1093–D1108PubMed
19.
go back to reference Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU (2001) Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86:4727–4730CrossRefPubMed Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU (2001) Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86:4727–4730CrossRefPubMed
20.
go back to reference Skene DJ, Lockley SW, Arendt J (1999) Melatonin in circadian sleep disorders in the blind. Biol Signals Recept 8:90–95CrossRefPubMed Skene DJ, Lockley SW, Arendt J (1999) Melatonin in circadian sleep disorders in the blind. Biol Signals Recept 8:90–95CrossRefPubMed
21.
go back to reference Cardinali DP, Gvozdenovich E, etal. (2002) A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol Lett 23:55–60PubMed Cardinali DP, Gvozdenovich E, etal. (2002) A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol Lett 23:55–60PubMed
22.
go back to reference Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 23:26–29 Cardinali DP, Brusco LI, Liberczuk C, Furio AM (2002) The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 23:26–29
23.
go back to reference Cardinali DP, Bortman GP, Liotta G, etal. (2002) A multifactorial approach employing melatonin to accelerate resynchronization of sleep–wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res 32:41–46CrossRefPubMed Cardinali DP, Bortman GP, Liotta G, etal. (2002) A multifactorial approach employing melatonin to accelerate resynchronization of sleep–wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J Pineal Res 32:41–46CrossRefPubMed
24.
go back to reference Arendt J (2003) Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 15:427–431CrossRefPubMed Arendt J (2003) Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 15:427–431CrossRefPubMed
25.
go back to reference Beaumont M, Batejat D, Pierard C, etal. (2004) Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol 96:50–58PubMed Beaumont M, Batejat D, Pierard C, etal. (2004) Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol 96:50–58PubMed
26.
go back to reference Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev CD001520 Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev CD001520
27.
go back to reference Lewy AJ, Ahmed S, Sack RL (1996) Phase shifting the human circadian clock using melatonin. Behav Brain Res 73:131–134PubMed Lewy AJ, Ahmed S, Sack RL (1996) Phase shifting the human circadian clock using melatonin. Behav Brain Res 73:131–134PubMed
28.
go back to reference McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV (2000) Treatment of sleep disturbance in Alzheimer’s disease. Sleep Med Rev 4:603–628CrossRefPubMed McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV (2000) Treatment of sleep disturbance in Alzheimer’s disease. Sleep Med Rev 4:603–628CrossRefPubMed
29.
go back to reference Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M (1999) Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep–waking. Biol Psychiatry 45:417–421CrossRefPubMed Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M (1999) Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep–waking. Biol Psychiatry 45:417–421CrossRefPubMed
30.
go back to reference Magri F, Sarra S, Cinchetti W, etal. (2004) Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 36:256–261CrossRefPubMed Magri F, Sarra S, Cinchetti W, etal. (2004) Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 36:256–261CrossRefPubMed
31.
go back to reference Hoogendijk WJ, van Someren EJ, Mirmiran M, etal. (1996) Circadian rhythm-related behavioral disturbances and structural hypothalamic changes in Alzheimer’s disease. Int Psychogeriatr 8:245–252PubMed Hoogendijk WJ, van Someren EJ, Mirmiran M, etal. (1996) Circadian rhythm-related behavioral disturbances and structural hypothalamic changes in Alzheimer’s disease. Int Psychogeriatr 8:245–252PubMed
32.
go back to reference Giubilei F, Patacchioli FR, Antonini G, etal. (2001) Altered circadian cortisol secretion in Alzheimer’s disease: clinical and neuroradiological aspects. J Neurosci Res 66:262–265CrossRefPubMed Giubilei F, Patacchioli FR, Antonini G, etal. (2001) Altered circadian cortisol secretion in Alzheimer’s disease: clinical and neuroradiological aspects. J Neurosci Res 66:262–265CrossRefPubMed
33.
go back to reference Harper DG, Stopa EG, McKee AC, etal. (2001) Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 58:353–360PubMed Harper DG, Stopa EG, McKee AC, etal. (2001) Differential circadian rhythm disturbances in men with Alzheimer disease and frontotemporal degeneration. Arch Gen Psychiatry 58:353–360PubMed
34.
go back to reference Swabb DF, Fliers E, Partiman TS (1985) The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342:37–44 Swabb DF, Fliers E, Partiman TS (1985) The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342:37–44
35.
go back to reference van Someren EJW (2000) Circadian rhythms and sleep in human aging. Chronobiol Int 17:233–243PubMed van Someren EJW (2000) Circadian rhythms and sleep in human aging. Chronobiol Int 17:233–243PubMed
36.
go back to reference Skene DJ, Swaab DF (2003) Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol 38:199–206CrossRefPubMed Skene DJ, Swaab DF (2003) Melatonin rhythmicity: effect of age and Alzheimer’s disease. Exp Gerontol 38:199–206CrossRefPubMed
37.
go back to reference Stopa EG, Volicer L, Kuo-Leblanc V, etal. (1999) Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 58:29–39PubMed Stopa EG, Volicer L, Kuo-Leblanc V, etal. (1999) Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 58:29–39PubMed
38.
go back to reference Iguchi H, Kato KI, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55:27–29 Iguchi H, Kato KI, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55:27–29
39.
go back to reference Dori D, Casale G, Solerte SB, etal. (1994) Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21:121–126PubMed Dori D, Casale G, Solerte SB, etal. (1994) Chrono-neuroendocrinological aspects of physiological aging and senile dementia. Chronobiologia 21:121–126PubMed
40.
go back to reference Girotti L, Lago M, Ianovsky O, etal. (2000) Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 29:138–142CrossRefPubMed Girotti L, Lago M, Ianovsky O, etal. (2000) Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 29:138–142CrossRefPubMed
41.
go back to reference Siegrist C, Benedetti C, Orlando A, etal. (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30:34–42CrossRefPubMed Siegrist C, Benedetti C, Orlando A, etal. (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30:34–42CrossRefPubMed
42.
go back to reference Mishima K, Okawa M, Hozumi S, Hishikawa Y (2000) Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest–activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 17:419–432CrossRefPubMed Mishima K, Okawa M, Hozumi S, Hishikawa Y (2000) Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest–activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 17:419–432CrossRefPubMed
43.
go back to reference Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P (2001) Actigraphic sleep–wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer’s disease. Chronobiol Int 18:513–524CrossRefPubMed Luboshitzky R, Shen-Orr Z, Tzischichinsky O, Maldonado M, Herer P, Lavie P (2001) Actigraphic sleep–wake patterns and urinary 6-sulfatoxymelatonin excretion in patients with Alzheimer’s disease. Chronobiol Int 18:513–524CrossRefPubMed
44.
go back to reference Mishima K, Okawa M, Shimizu T, Hishikawa Y (2001) Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 86:129–134CrossRefPubMed Mishima K, Okawa M, Shimizu T, Hishikawa Y (2001) Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J Clin Endocrinol Metab 86:129–134CrossRefPubMed
45.
go back to reference Skene DJ, Vivien-Roels B, Sparks DL, etal. (1990) Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res 528:170–174CrossRefPubMed Skene DJ, Vivien-Roels B, Sparks DL, etal. (1990) Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res 528:170–174CrossRefPubMed
46.
go back to reference Uchida K, Okamoto N, Ohara K, Morita Y (1996) Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 717:154–159CrossRefPubMed Uchida K, Okamoto N, Ohara K, Morita Y (1996) Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 717:154–159CrossRefPubMed
47.
go back to reference Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF (1999) Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon 4/4 genotype. J Clin Endocrinol Metab 84:323–327CrossRefPubMed Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF (1999) Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon 4/4 genotype. J Clin Endocrinol Metab 84:323–327CrossRefPubMed
48.
go back to reference Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y (1999) Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry 45:1646–1652CrossRefPubMed Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y (1999) Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry 45:1646–1652CrossRefPubMed
49.
go back to reference Ferrari E, Arcaini A, Gornati R, etal. (2000) Pineal and pituitary–adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 35:1239–1250CrossRefPubMed Ferrari E, Arcaini A, Gornati R, etal. (2000) Pineal and pituitary–adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 35:1239–1250CrossRefPubMed
50.
go back to reference Savaskan E, Olivieri G, Meier F, etal. (2002) Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer’s disease patients. J Pineal Res 32:59–62CrossRefPubMed Savaskan E, Olivieri G, Meier F, etal. (2002) Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer’s disease patients. J Pineal Res 32:59–62CrossRefPubMed
51.
go back to reference Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF, (2003) Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35:125–130CrossRefPubMed Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF, (2003) Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35:125–130CrossRefPubMed
52.
go back to reference Taylor JL, Friedman L, Sheikh J, Yesavage JA (1997) Assessment and management of “sundowning” phenomena. Semin Clin Neuropsychiatry 2:113–122PubMed Taylor JL, Friedman L, Sheikh J, Yesavage JA (1997) Assessment and management of “sundowning” phenomena. Semin Clin Neuropsychiatry 2:113–122PubMed
53.
go back to reference McGaffigan S, Bliwise DL (1997) The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging 10:10–17PubMed McGaffigan S, Bliwise DL (1997) The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging 10:10–17PubMed
54.
go back to reference Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–134PubMed Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45:115–134PubMed
56.
go back to reference Fainstein I, Bonetto A, Brusco LI, Cardinali DP (1997) Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 58:990–1000CrossRef Fainstein I, Bonetto A, Brusco LI, Cardinali DP (1997) Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 58:990–1000CrossRef
57.
go back to reference Jean-Louis G, von Gizycki H, Zizi F (1998) Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 25:177–183PubMed Jean-Louis G, von Gizycki H, Zizi F (1998) Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 25:177–183PubMed
58.
go back to reference Brusco LI, Marquez M, Cardinali DP (1998) Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuroendocrinol Lett 19:111–115 Brusco LI, Marquez M, Cardinali DP (1998) Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuroendocrinol Lett 19:111–115
59.
go back to reference Brusco LI, Marquez M, Cardinali DP (1998) Monozygotic twins with Alzheimer’s disease treated with melatonin: case report. J Pineal Res 25:260–263PubMed Brusco LI, Marquez M, Cardinali DP (1998) Monozygotic twins with Alzheimer’s disease treated with melatonin: case report. J Pineal Res 25:260–263PubMed
60.
go back to reference Cohen-Mansfield J, Garfinkel D, Lipson S (2000) Melatonin for treatment of sundowning in elderly persons with dementia. Arch Gerontol Geriatr 31:65–76CrossRefPubMed Cohen-Mansfield J, Garfinkel D, Lipson S (2000) Melatonin for treatment of sundowning in elderly persons with dementia. Arch Gerontol Geriatr 31:65–76CrossRefPubMed
61.
go back to reference Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R (2004) Melatonin treatment of day–night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 24:456–459PubMed Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R (2004) Melatonin treatment of day–night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 24:456–459PubMed
62.
go back to reference Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S (2003) Double blind study of melatonin effects on the sleep–wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70:334–341CrossRefPubMed Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S (2003) Double blind study of melatonin effects on the sleep–wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70:334–341CrossRefPubMed
63.
go back to reference Singer C, Tractenberg RE, Kaye J, etal. (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 26:893–901PubMed Singer C, Tractenberg RE, Kaye J, etal. (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 26:893–901PubMed
64.
go back to reference Monti JM, Alvarino F, Cardinali D, Savio I, Pintos A (1999) Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 28:85–98CrossRefPubMed Monti JM, Alvarino F, Cardinali D, Savio I, Pintos A (1999) Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriatr 28:85–98CrossRefPubMed
65.
go back to reference van Coevorden A, Mockel J, Laurent E, etal. (1991) Neuroendocrine rhythms and sleep in aging men. Am J Physiol 260:E651–E661PubMed van Coevorden A, Mockel J, Laurent E, etal. (1991) Neuroendocrine rhythms and sleep in aging men. Am J Physiol 260:E651–E661PubMed
66.
go back to reference Pappolla MA, Sos M, Omar RA, etal. (1997) Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17:1683–1690PubMed Pappolla MA, Sos M, Omar RA, etal. (1997) Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17:1683–1690PubMed
67.
go back to reference Daniels WM, van Rensburg SJ, van Zyl JM, Taljaard JJ (1998) Melatonin prevents beta-amyloid-induced lipid peroxidation. J Pineal Res 24:78–82PubMed Daniels WM, van Rensburg SJ, van Zyl JM, Taljaard JJ (1998) Melatonin prevents beta-amyloid-induced lipid peroxidation. J Pineal Res 24:78–82PubMed
68.
go back to reference Song W, Lahiri DK (1997) Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 9:75–92PubMed Song W, Lahiri DK (1997) Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 9:75–92PubMed
69.
go back to reference Furio AM, Cutrera RA, Castillo TV, etal. (2002) Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25–35 in the suprachiasmatic nuclei. Cell Mol Neurobiol 22:699–709CrossRefPubMed Furio AM, Cutrera RA, Castillo TV, etal. (2002) Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25–35 in the suprachiasmatic nuclei. Cell Mol Neurobiol 22:699–709CrossRefPubMed
70.
go back to reference Matsubara E, Bryant-Thomas T, Pacheco QJ, etal. (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem 85:1101–1108CrossRefPubMed Matsubara E, Bryant-Thomas T, Pacheco QJ, etal. (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem 85:1101–1108CrossRefPubMed
Metadata
Title
The Use of Chronobiotics in the Resynchronization of the Sleep–wake Cycle
Authors
Daniel P. Cardinali
Analía M. Furio
María P. Reyes
Luis I. Brusco
Publication date
01-05-2006
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 4/2006
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-005-9009-2

Other articles of this Issue 4/2006

Cancer Causes & Control 4/2006 Go to the issue

Special Section on Cancer and Rhythm

Tumor Suppression by the Mammalian Period Genes

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine